Showing results (51-60 of 167) with videos related to
Sort By:
Pageof 17
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabMaria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of ResistanceHelena A Yu, Ken Suzawa, Emmet Jordan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.Science Advances|November 23, 2022
Widespread hypertranscription in aggressive human cancersMatthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.Nature Communications|July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapyAkane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.Cancer Medicine|May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumabNarek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.Pageof 17